Dotinurad restores exacerbated kidney dysfunction in hyperuricemic patients with chronic kidney disease

Abstract

Abstract Background In this study, we aimed to clarify the beneficial effects of urate-lowering treatment with the novel agent dotinurad on renal function in patients with chronic kidney disease (CKD) and hyperuricemia (HUA).Methods Thirty-five patients with CKD (mean age 65.4 ± 14.8 years, 23 men) diagnosed with HUA were recruited. Changes in eGFR before and after dotinurad administration were assessed.Results During the 3-month observation period, mean eGFR (mL/min/1.73 m2) declined significantly from 35.5 ± 16.8 to 31.8 ± 16.4, whereas it recovered to 36.5 ± 17.5 after dotinurad administration. The increase in eGFR after dotinurad administration was correlated with a decrease in sUA (R = 0.375, p = 0.0263).Conclusion Dotinurad administration to patients with CKD and HUA appears to be beneficial in restoring kidney function. Dotinurad may represent a potential medication for the prevention of kidney function decline caused by HUA.